LEXINGTON, Mass., Nov. 27, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the following upcoming conferences:
Piper Jaffray and Deutsche Bank are both using an "unplugged" fireside chat format for the presentation sessions. Dan Passeri, Curis' President and Chief Executive Officer, will provide a brief overview of the Company's business strategy and pipeline of small molecule targeted cancer drug candidates, after which an equity analyst will moderate a question and answer session.
The audio webcasts will be archived shortly after the live events and available for 30 days following the conference.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.
The Curis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11347
CONTACT: For More Information:
Michael P. Gray
Chief Financial Officer